had their immunological status re-evaluated. diagnosis of specific antibody deficiency should Patients with a confirmed IgG deficiency have be confirmed following cessation of become eligible under another indication immunoglobulin therapy. (e.g. primary immunodeficiency with antibody deficiency). Patients without a Existing patient on IgG therapy funded under confirmed IgG deficiency have ceased IVIg the National Blood Arrangements in Australia therapy. AND With clinically active bronchiectasis or Clinically active bronchiectasis and/or suppurative lung disease over the suppurative lung disease proven by radiology previous 12 months: To be eligible to (see note) receive IVIg for a further 12 months, the following is required: AND Written confirmation from the treating clinical immunologist that : The patient has had demonstrated clinical an annual review has been undertaken; benefit over the last 12 months and has had at the patient has demonstrated clinical least 2 episodes of infection requiring benefit; and antibiotics a trial period of cessation of IVIg for the AND purpose of immunological evaluation is medically contraindicated on safety A cessation of therapy will be undertaken grounds. next September or October to undertake an AND immunological evaluation, unless a trial period Written confirmation by a second physician of cessation of immunoglobulin therapy for that cessation of IVIg for the purpose the purpose of immunological evaluation is of immunological evaluation is medically contraindicated on safety grounds medically contraindicated on safety (e.g. neutropenia, or other cytopenia, grounds. immunosuppressant medications or clinically
had their immunological status re-evaluated. Patients with a confirmed IgG deficiency have become eligible under another indication (e.g. primary immunodeficiency with antibody deficiency). Patients without a confirmed IgG deficiency have ceased IVIg therapy. With clinically active bronchiectasis or suppurative lung disease over the previous 12 months: To be eligible to receive IVIg for a further 12 months, the following is required: Written confirmation from the treating clinical immunologist that : an annual review has been undertaken; the patient has demonstrated clinical benefit; and a trial period of cessation of IVIg for the purpose of immunological evaluation is medically contraindicated on safety grounds. AND Written confirmation by a second physician that cessation of IVIg for the purpose of immunological evaluation is medically contraindicated on safety grounds. diagnosis of specific antibody deficiency should be confirmed following cessation of immunoglobulin therapy. Existing patient on IgG therapy funded under the National Blood Arrangements in Australia AND Clinically active bronchiectasis and/or suppurative lung disease proven by radiology (see note) AND The patient has had demonstrated clinical benefit over the last 12 months and has had at least 2 episodes of infection requiring antibiotics AND A cessation of therapy will be undertaken next September or October to undertake an immunological evaluation, unless a trial period of cessation of immunoglobulin therapy for the purpose of immunological evaluation is medically contraindicated on safety grounds (e.g. neutropenia, or other cytopenia, immunosuppressant medications or clinically
specific-antibody-deficiency-sad.DOCX